Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for SXT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for SXT and 80,000+ other tickers.
See exactly how SXT's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SXT and 80,000+ other tickers.
Sensient Technologies Corporation, operating alongside its various subsidiaries, specializes in the creation, production, and global distribution of colors, flavorings, and an array of other specialized ingredients. The company's extensive market presence spans across North America, Europe, the Asia Pacific region, and numerous other international territories. Its operations are strategically organized into three main divisions: the Flavors & Extracts Group, the Color Group, and the Asia Pacific Group. For the food, beverage, personal care, and household product sectors, Sensient supplies…
TAIZHOU, China, Oct. 22, 2026 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, at a ratio of 1-for-100, effective on October 26, 2026 (the "Share Consolidation"). The Company's Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on October 26, 2026.
TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026 (the "Offering"). Under the termination letter agreement, the Company and the purchasers have terminated in full the additional purchase right set forth in Section 2.4 of the securities purchase agreement entered into in connection with the Offering.
MILWAUKEE--(BUSINESS WIRE)--Sensient Technologies Corporation (NYSE: SXT) will hold its earnings call and webcast to discuss 2026 third quarter results at 8:30 a.m. CDT on Friday, October 30, 2026. Investors may access the live webcast on the Company's web site at investor.sensient.com. Alternatively, investors may join the conference call by contacting Chorus Call Inc. at (844) 492-3726 or (412) 317-1078. A webcast replay will be available on the Company's web site following the call. The call.
TAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the company, no par value per share (the "Shares") (or pre-funded warrants in lieu thereof), at a purchase price of $1.50 per share in a registered direct offering. The Company also agreed to issue to the same investors 8,000,000 warrants (the "Warrants") with an exercise price of $1.50 per share.
